摘要Objective:Qiliqiangxin(QLQX)capsule,a traditional Chinese medicine used for treating heart failure(HF),can modulate inflammatory cytokines in rats with myocardial infarction.However,its immune-regulating effect on dilated cardiomyopathy(DCM)remains unknown.The aim of this study was to investigate whether QLQX has a unique regulatory role in the imbalance of pro-and anti-inflammatory cytokines in patients with DCM.Methods:The QLQX-DCM is a randomized,double-blind trial conducted at 24 tertiary hospitals in China.A total of 345 patients with newly diagnosed virus-induced DCM were randomly assigned to receive QLQX capsules or placebo while receiving optimal medical therapy for HF.The primary endpoints were changes in plasma inflammatory cytokines and improvements in left ventricular ejection fraction(LVEF)and left ventricular end-diastolic diameter(LVEDd)over the 12-month treatment.Results:At the 12-month follow-up,the levels of IFN-γ,1L-17,TNF-α,and IL-4 decreased significantly,while the level of IL-10 increased in both groups compared with baselines(all P＜0.0001).Furthermore,these changes,coupled with improvements in LVEF,NT-proBNP and New York Heart Association(NYHA)functional classification,excluding the LVEDd in the QLQX group,were greater than those in the placebo group(all P＜0.001).Additionally,compared with placebo,QLQX treatment also reduced all-cause mortality and rehospitalization rates by 2.17％and 2.28％,respectively,but the difference was not statistically significant.Conclusion:QLQX has the potential to alleviate the imbalance of inflammatory cytokines in patients with DCM,potentially leading to further improvements in cardiac function when combined with anti-HF standard medications.